Table 6 Clinical outcomes and Follow-Up metrics for pediatric patients with paroxysmal sympathetic hyperactivity
Variables | Counts | % of Total |
|---|---|---|
Number of FU visits (N = 40) | ||
Mean (SD) | 3.075 | 3.3 |
Median (IQR) | 2 | (0.75, 4) |
Maximum interval between FU visit/days (N = 37) | ||
Mean (SD) | 40.5676 | 35.619 |
Median (IQR) | 30 | (21, 60) |
Response (N = 40) | ||
Improved | 35 | 87.5% |
No change | 5 | 12.5% |
Interval between episodes (N = 31) | ||
Mean (SD) | 39.2581 | 31.83 |
Median (IQR) | 30 | (21, 60) |
Mortality (N = 41) | ||
Yes | 14 | 34.1% |
No | 27 | 65.9% |
Complications | ||
none | 26 | 61.9% |
Yes | 16 | 38.1% |
sedation | 7 | 16.6% |
Bradycardia | 4 | 9.5% |
mildly elevated liver transaminase | 2 | 4.8% |
Increased secretions | 2 | 4.8% |
DCL | 2 | 4.8% |
Hypotension | 1 | 2.4% |
Weight gain | 1 | 2.4% |
Respiratory depression | 1 | 2.4% |
urinary retention | 1 | 2.4% |
Ongoing admission (N = 41) | ||
Ongoing admission | 4 | 9.8% |
Discharged | 37 | 90.2% |
Number of hospital admissions (N = 37) | ||
Mean (SD) | 3.6757 | 4.865 |
Median (IQR) | 2 | (0, 5) |
Number of ER visits (N = 37) | ||
Mean (SD) | 4.7568 | 6.26 |
Median (IQR) | 2 | (0, 8) |